Insilico Medicine and MIKADO team up to find new treatments for cystinosis

A team led by researchers at the Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (Zurich, Switzerland) has used Insilico Medicine's generative artificial intelligence (AI) target discovery engine, PandaOmics, to identify actionable drug targets for the lysosomal storage disease cystinosis and to validate them in preclinical models of the disease.

Related Keywords

Italy ,Switzerland ,Zurich ,Züsz ,Olivier Devuyst ,Alessandro Luciani ,Alex Zhavoronkov ,Danielle Ellis ,Microsoft Research ,University Of Zurich ,Cystinosis Research Foundation Irvine ,University Of Trento Centre For Computational ,Program Innovative Therapies In Rare Diseases ,Drug Administration ,Nature Communications ,Inherited Kidney Disorders ,Insilico Medicine ,Microsoft Research University ,Trento Centre ,Systems Biology ,Cystinosis Research Foundation ,Program Innovative Therapies ,Rare Diseases ,Medicine Founder ,Professor Olivier Devuyst ,